STOCK TITAN

Profound Medical Corp. - PROF STOCK NEWS

Welcome to our dedicated page for Profound Medical news (Ticker: PROF), a resource for investors and traders seeking the latest updates and insights on Profound Medical stock.

Profound Medical Corp. (PROF) is a leading Canadian medical device company, renowned for its innovative, minimally invasive procedures targeting prostate cancer. The company has developed the highly advanced TULSA-PRO system, which integrates real-time MRI, robotically driven transurethral therapeutic ultrasound, and closed-loop thermal feedback control to ablate prostate tissue. This technology offers a patient-specific, precise treatment with short recovery times and low morbidity rates. Currently, Profound Medical is demonstrating the potential of this technology through various clinical trials.

The company's primary focus is on the development and commercialization of customizable, incision-free therapeutic systems for image-guided ablation of diseased tissue. Profound Medical leverages the existing imaging infrastructure within the healthcare system, making its solutions highly adaptable and efficient. The TULSA-PRO system consists of both one-time-use devices and durable equipment that work with existing MRI scanners, providing a seamless integration into current medical practices.

Profound Medical is in a commercial stage and continues to invest in research and development to enhance its platform technologies. For the year ending December 31, 2023, the company dedicated approximately $14.4 million to R&D, reflecting a slight decrease from the previous year. This reduction was primarily due to lower salaries, benefits, and office supplies, while there was a notable increase in clinical trial costs, materials, consulting fees, and other related expenses.

The company's latest news typically includes updates on clinical trials, financial performance, and strategic developments. Investors and stakeholders can expect regular communication on these fronts, keeping them informed about the company's progress and future directions.

Rhea-AI Summary
Profound Medical Corp. to host Analyst & Investor Day event on October 13, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Profound Medical Corp. to present business update at Cantor Global Healthcare Conference on September 26, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
conferences
-
Rhea-AI Summary
Profound Medical Corp. establishes an at-the-market equity program to issue and sell up to US$30,000,000 of common shares. The TSX has conditionally approved the listing of the Common Shares. The Company intends to use the net proceeds for continued commercialization and development of its medical systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.5%
Tags
none
Rhea-AI Summary
Profound Medical Corp. reported financial results for Q2 2023, with a 38% increase in recurring revenue compared to Q2 2022. The company expects increased U.S. TULSA adoption and recurring revenue growth for the remainder of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.97%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.3%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.39%
Tags

FAQ

What is the current stock price of Profound Medical (PROF)?

The current stock price of Profound Medical (PROF) is $7.55 as of November 22, 2024.

What is the market cap of Profound Medical (PROF)?

The market cap of Profound Medical (PROF) is approximately 186.4M.

What does Profound Medical Corp. do?

Profound Medical Corp. develops and markets minimally invasive, incision-free therapeutic systems for the image-guided ablation of diseased tissue.

What is the TULSA-PRO system?

The TULSA-PRO system is a device developed by Profound Medical that uses real-time MRI, robotically driven transurethral therapeutic ultrasound, and closed-loop thermal feedback to ablate prostate tissue.

What makes Profound Medical's technology unique?

Their technology combines MRI imaging with precise ultrasound and thermal feedback for targeted, patient-specific treatment, ensuring lower morbidity and faster recovery.

Is Profound Medical a commercial-stage company?

Yes, Profound Medical is a commercial-stage company focused on developing and marketing its therapeutic systems.

What were Profound Medical’s R&D expenditures in 2023?

In 2023, Profound Medical’s R&D expenditures were approximately $14.4 million.

How does Profound Medical's system integrate with existing medical infrastructure?

The TULSA-PRO system integrates with existing MRI scanners, making it adaptable to current healthcare imaging infrastructures.

What are the benefits of Profound Medical's TULSA-PRO system for patients?

The system offers precise treatment with short recovery times and low morbidity, tailored to the patient's specific anatomy and pathology.

Where can I find more information about Profound Medical's developments?

For more information, visit Profound Medical Corp.'s official website at profoundmedical.com.

What are the latest updates from Profound Medical Corp.?

Latest updates include news on clinical trials, financial performance, and strategic developments.

How can I contact Profound Medical Corp. for investor relations?

You can contact Stephen Kilmer for investor relations at skilmer@profoundmedical.com or call 647.872.4849.

Profound Medical Corp.

Nasdaq:PROF

PROF Rankings

PROF Stock Data

186.44M
22.41M
8.6%
43.82%
1.39%
Medical Devices
Healthcare
Link
United States of America
Mississauga